Pharmacy Technician Pulse

Idaho hospital to stop obstetrical services citing doc shortages, fewer births and 'political climate'

Fierce Healthcare

MARCH 23, 2023

Idaho hospital to stop obstetrical services citing doc shortages, fewer births and 'political climate' hlandi Thu, 03/23/2023 - 16:12

Hospitals

Political headwinds grow against CMMI accelerated approval drug price model

Fierce Healthcare

MARCH 10, 2023

Political headwinds grow against CMMI accelerated approval drug price model rking Fri, 03/10/2023 - 16:16

Opinion: How the Biden administration’s Covid preparedness policies could narrow America’s political divide

STAT

JANUARY 31, 2023

5 subvariants in May 2022, strongly supports a new unifying reality that combines sound science and good politics. This will also resonate with a majority of Americans of all political persuasions and bring us closer together — or at least not further widen the breach. Read the rest…

Communication

An unlikely alliance? Pfizer CEO gave political cash to Senate GOP candidate Dr. Oz

Fierce Pharma

MARCH 9, 2023

Pfizer CEO gave political cash to Senate GOP candidate Dr. Oz zbecker Thu, 03/09/2023 - 10:51 An unlikely alliance?

Mandy Cohen, seen as next CDC director, would bring political chops to an agency lacking them

STAT

JUNE 15, 2023

The Atlanta-based CDC has always prided itself at being at a remove from Washington, and the politics that engulf it. The Centers for Disease Control and Prevention may be about to undergo a paradigm shift with the anticipated appointment of former North Carolina health secretary Mandy Cohen as the agency’s next director.

Understanding the politics of drug pricing in the United States

pharmaphorum

MARCH 27, 2024

Brandon Newman, CEO of healthcare analytics firm Xevant, joins host Jonah Comstock on today’s episode of the pharmaphorum podcast.

As conservative views collide with science, doctors find themselves navigating political landmines

STAT

OCTOBER 3, 2023

WASHINGTON — It started with a tweet: A year-old, 43-second clip of Kevin Wang talking about how parents and teachers can help affirm and support a child’s gender identity, encouraging children to explore. The vitriolic tweets were swift, and they snowballed.

Hospitals

Psychedelic Medicine: Developments, Evaluations, and Political Enthusiasm

PharmExec

NOVEMBER 9, 2023

A look into the potential effect of psychedelic drugs on various illnesses, such as mental health conditions.

The FDA is mulling an OTC approval for a birth control. Will politics factor in?

PharmaVoice

AUGUST 15, 2022

Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.

FDA

Opinion: Clients bring politics into the therapy room. Here’s what that means for the therapist

STAT

DECEMBER 8, 2023

“Can I tell you what I really think about what’s going on?” ” she asks, looking down and clutching her coffee, her right sneaker tapping. I had been fairly sure about two things ahead of our session: one, that she would talk about the Conflict, and two, that I would dislike what she was going to say.

Ending racial health disparities hinges on penalties, political will, experts say

STAT

JULY 12, 2023

The nation’s widespread racial health disparities won’t be erased without changes to how health care systems are funded and accredited, more public and financial accountability for poor patient outcomes, and more work to overturn the income inequality and residential segregation tied to poorer health and lower life expectancy for many (..)

Insurance

NHS drug shortages are partly a political failure | Letters

The Guardian - Pharmaceutical Industry

JANUARY 22, 2024

Britain is pushing for patent changes in India that could increase the cost of generic drugs, writes Tim Bierley ; plus letters from readers on the human cost of shortages The shortage of key drugs in the National Health Service ( NHS medicines shortage putting lives at risk, pharmacists warn, 14 January ) could get even worse if the UK government (..)

Generic Medicine

Pandemic and Politics Shaped Pharma and FDA in 2022

BioPharm

DECEMBER 1, 2022

Health crises, political tension, and budget concerns were major challenges.

FDA

FDA wants to hear your thoughts on advisory committees

STAT

APRIL 30, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, I’m up bright and early today to report on earnings, with the help of some coffee (with pasteurized milk) and the soundtrack for the new Challengers movie.

FDA

The biotech news you need to read this morning

STAT

MAY 2, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’re nearing the end of my second week writing this newsletter. I want to know what you think! Share your feedback in this survey if you haven’t already.

Pharma has over $500B in capital for deals

STAT

MAY 8, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today we ponder, how much will the advisory committee meeting for Lilly’s donanemab matter? Send me your thoughts, and as always, any ideas or tips: elaine.chen@statnews.com.

FDA

Vertex starts gene therapy Casgevy in five patients

STAT

MAY 7, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

FDA

ICER casts doubt on Sarepta’s DMD gene therapy

STAT

MAY 3, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! A crowdsourced Readout today, to be sure, with contributions from STAT’s Jason Mast, Elaine Chen, and Jonathan Wosen.

FDA

Pfizer’s plot to win the RSV vaccine race

STAT

APRIL 9, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an update on the biotech market, a look at the future of genome editing, and the evolving definition of “insider trading.”

Vaccines

The latest government crackdowns on biotech you need to know

STAT

MAY 1, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

FDA

An ugly fight over care for the poor in Texas

STAT

JANUARY 2, 2024

Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Power, politics, and care for the poor in Texas Local officials in Austin, Texas promised twelve years ago that if voters approved millions of dollars in new property taxes, it would be a win-win.

Medical Schools

Medical Schools Hospitals Insurance

Opinion: How do doctors’ personal political affiliations affect how they care for their patients?

STAT

JULY 24, 2023

This essay is adapted from “ Random Acts of Medicine: The Hidden Forces That Sway Doctors, Impact Patients, and Shape Our Health ,” out now from Doubleday. “H oney, I forgot to duck,” Ronald Reagan said to his wife as he was wheeled to the operating room of George Washington University Hospital on March 30, 1981.

Hospitals

Yet another big financing round in immunology

STAT

MAY 9, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congratulations on almost making it to the end of the week! For that, I have a little treat for you at the bottom of the newsletter. Read the rest…

FDA

Merck may have a competition for ever-scarce BCG

STAT

MAY 6, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning!

Biotechs heed political headwinds for drug pricing negotiations and partnerships

Pharmaceutical Technology

FEBRUARY 28, 2024

Biotechs need to navigate US-China relations when pursuing collaborations and drug manufacturing partnerships.

Opinion: STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more

STAT

APRIL 27, 2024

It is a commonsense reform, independent of one’s political leanings. Sebelius As a practicing oncologist, I wholeheartedly agree with the former HHS secretaries’ call to expand site-neutral payment policy. Read the rest…

Medical Schools

What’s Congress going to do with WuXi?

STAT

MARCH 29, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at key Supreme Court decision, the latest biotech IPO, and intrigue over Chinese outsourcing. Read the rest…

FDA

Biohaven’s data delay degrades stock price

STAT

APRIL 16, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we dig into Biohaven’s plans and see Humira biosimilar prescriptions shoot up. Read the rest…

EU adviser says Illumina merger was not problematic

STAT

MARCH 22, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi, it’s Meghana. Today, Illumina finally finds an advocate in the EU, a CRISPRed pig kidney is transplanted into a living human, and more. Read the rest…

FDA

BioNTech is having its Pfizer moment

STAT

MARCH 21, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with yet another megaround in biotech, a preview of some hotly anticipated data, and the perils of declining revenue. Read the rest…

Opinion: To rebuild trust in public health: Better communication, fewer mandates, and small wins

STAT

APRIL 11, 2024

It’s no surprise in today’s corrosive political environment that trust in government is near an all-time low. That’s a big problem. Communities with more trust during the Covid-19 pandemic had fewer deaths and less economic devastation.

Communication

The latest updates on cancer research from the weekend

STAT

APRIL 8, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi, it’s Meghana. Lots happened this past weekend!

Expanding the WTO intellectual property waiver will hurt American jobs

PhRMA

NOVEMBER 9, 2022

The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was a political and ineffective measure that does not address the true barriers to vaccine equity.

Vaccines

How resurrecting extinct species might impact medicine

STAT

APRIL 4, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S.

New data on liquid biopsy for colorectal cancer detection still underwhelms

STAT

APRIL 3, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Read the rest…

What happens when an approved drug doesn’t work?

STAT

MARCH 15, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more. Read the rest…

FDA

Intelligence officials warned lawmakers WuXi AppTec furnished China with client's intellectual property: Reuters

Fierce Pharma

MARCH 28, 2024

suggests intelligence officials and lawmakers may have good reason to be concerned about the CDMO’s potential political ties to its home country. . | An alleged development in the national security crackdown against WuXi AppTec and a handful of other Chinese companies in the U.S.

Wegovy and Zepbound get primetime treatment

STAT

MARCH 19, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at a pioneering new gene therapy, the plight of WuXi AppTec, and a rough month for biotech’s neuroscience renaissance. Read the rest…

Where’s Lilly’s Alzheimer’s approval?

STAT

MARCH 5, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here. I’d like to heartily recommend you check out Part 1 of The War on Recovery , a yearlong STAT investigation into how the U.S.

Novo is building a really big computer

STAT

MARCH 20, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest megaround in biotech venture capital, a rough month for biotech’s neuroscience renaissance, and Novo Nordisk’s big computer.

FDA

UnitedHealth’s Andrew Witty gets no pity in Congress

STAT

MAY 2, 2024

Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. You’re reading the web edition of D.C. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Payment Processing

Payment Processing Insurance

Banning WuXi is more complicated than it might sound

STAT

MARCH 7, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a curious case before the FDA, a State of the Union preview, and the latest IPO to test biotech’s recent resurgence. Read the rest…

FDA

GSK pill works in uncomplicated gonorrhea

STAT

FEBRUARY 27, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. It’s Meghana.

FDA

Contineum Therapeutics files for IPO

STAT

MARCH 18, 2024

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies.

Labelling

Labelling FDA

Idaho hospital to stop obstetrical services citing doc shortages, fewer births and 'political climate'

Political headwinds grow against CMMI accelerated approval drug price model

Trending Sources

Opinion: How the Biden administration’s Covid preparedness policies could narrow America’s political divide

An unlikely alliance? Pfizer CEO gave political cash to Senate GOP candidate Dr. Oz

Mandy Cohen, seen as next CDC director, would bring political chops to an agency lacking them

Understanding the politics of drug pricing in the United States

As conservative views collide with science, doctors find themselves navigating political landmines

Psychedelic Medicine: Developments, Evaluations, and Political Enthusiasm

The FDA is mulling an OTC approval for a birth control. Will politics factor in?

Opinion: Clients bring politics into the therapy room. Here’s what that means for the therapist

Ending racial health disparities hinges on penalties, political will, experts say

NHS drug shortages are partly a political failure | Letters

Pandemic and Politics Shaped Pharma and FDA in 2022

FDA wants to hear your thoughts on advisory committees

The biotech news you need to read this morning

Pharma has over $500B in capital for deals

Vertex starts gene therapy Casgevy in five patients

ICER casts doubt on Sarepta’s DMD gene therapy

Pfizer’s plot to win the RSV vaccine race

The latest government crackdowns on biotech you need to know

An ugly fight over care for the poor in Texas

Opinion: How do doctors’ personal political affiliations affect how they care for their patients?

Yet another big financing round in immunology

Merck may have a competition for ever-scarce BCG

Biotechs heed political headwinds for drug pricing negotiations and partnerships

Opinion: STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more

What’s Congress going to do with WuXi?

Biohaven’s data delay degrades stock price

EU adviser says Illumina merger was not problematic

BioNTech is having its Pfizer moment

Opinion: To rebuild trust in public health: Better communication, fewer mandates, and small wins

The latest updates on cancer research from the weekend

Expanding the WTO intellectual property waiver will hurt American jobs

How resurrecting extinct species might impact medicine

New data on liquid biopsy for colorectal cancer detection still underwhelms

What happens when an approved drug doesn’t work?

Intelligence officials warned lawmakers WuXi AppTec furnished China with client's intellectual property: Reuters

Wegovy and Zepbound get primetime treatment

Where’s Lilly’s Alzheimer’s approval?

Novo is building a really big computer

UnitedHealth’s Andrew Witty gets no pity in Congress

Banning WuXi is more complicated than it might sound

GSK pill works in uncomplicated gonorrhea

Contineum Therapeutics files for IPO

Stay Connected